RecruitingPhase 1NCT07517198

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Assess Safety, Tolerability, and Efficacy of EXS74539 as Monotherapy in Participants With Select Solid Tumors

Sponsor

Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

Enrollment

40 participants

Start Date

Apr 1, 2026

Study Type

INTERVENTIONAL

Conditions

Solid Tumor

Summary

The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.

Eligibility

Min Age: 18 Years

Inclusion Criteria14

Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Histologically confirmed diagnosis of the following solid tumors:
SCLC
High grade neuroendocrine or small cell carcinomas of non-lung origin
Non-small cell lung cancer \[NSCLC\]
Prostate cancer
Ovarian cancer
Renal carcinoma \[clear and non-clear cell\]
Head and neck squamous cell carcinoma
Hepatic cancer
Gastric cancer
Triple-negative breast cancer \[TNBC\]
Participant disease should have progressed, relapsed or the participants should have been intolerant to at least one prior standard systemic therapy for their respective underlying malignancy.
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

Exclusion Criteria5

Any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the participant's safety or ability to participate in the study.
Symptomatic brain metastases, leptomeningeal metastases, or spinal cord compression due to disease. Participants with brain metastases must be clinically stable and off corticosteroids and anticonvulsants for ≥1 month prior to study treatment and not require any specific intervention for brain metastases.
Active and clinically significant infection requiring systemic antibacterial, antiviral, or antifungal therapy <7 days of the first scheduled dose of the study treatment.
Significant cardiac abnormalities.
Major surgery within 28 days prior to the start of study treatment.

Interested in this trial?

Get notified about updates and connect with the research team.